Biolinq Incorporated has received De Novo Classification from the US Food and Drug Administration (FDA) for its lead product, Biolinq Shine™, marking a major regulatory milestone for the company.
This decision provides a pathway to scale a new generation of wearable sensors designed to be simple, comfortable, and widely accessible.
The Biolinq Shine is a wearable biosensor for people with type 2 diabetes not dependent on insulin, combining glucose, activity, and sleep tracking in one device.
Worn as a forearm patch, it provides real-time glucose feedback via a color-coded LED visible without a smartphone, with additional sleep and activity insights available in a mobile app.
Unlike filament-based monitors, it requires no subcutaneous needle; its microsensor array is up to 20 times shallower than conventional systems, offering a simpler, more comfortable experience to encourage long-term use and confidence in continuous monitoring.
The company sees the FDA’s classification as an important step towards expanding its multi-analyte biosensor platform. The technology is intended not only to support people living with diabetes but also to promote broader improvements in metabolic health.
The American Diabetes Association recommends that individuals with diabetes aim to maintain glucose within a target range at least 70% of the time, a goal that can be difficult to achieve with occasional glucose checks.
Continuous monitoring solutions such as Biolinq Shine are expected to make it easier for people to track and manage glucose levels effectively.
